Compare USAS & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USAS | ZYME |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.9B |
| IPO Year | 2004 | 2022 |
| Metric | USAS | ZYME |
|---|---|---|
| Price | $7.29 | $24.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $6.50 | ★ $38.90 |
| AVG Volume (30 Days) | ★ 5.0M | 530.2K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $105,965,000.00 |
| Revenue This Year | $174.68 | $183.10 |
| Revenue Next Year | $53.17 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 38.87 |
| 52 Week Low | $0.56 | $11.02 |
| 52 Week High | $10.50 | $29.75 |
| Indicator | USAS | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 63.59 | 39.64 |
| Support Level | $6.67 | $22.28 |
| Resistance Level | $8.66 | $27.54 |
| Average True Range (ATR) | 0.43 | 1.28 |
| MACD | 0.20 | -0.52 |
| Stochastic Oscillator | 89.36 | 17.45 |
Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets, which are also its reporting segments, are the Cosala operations, the Galena Complex, and Relief Canyon. It also holds interests in the San Felipe Development Project located in Sonora, Mexico. The Cosala operations segment, which derives maximum revenue, operates in Mexico, while the Galena Complex and Relief Canyon segments operate in the United States.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.